Tag Archive: CA)

Feb 06

The addition of evolocumab (Amgen, Thousand Oaks, CA) to a statin

The addition of evolocumab (Amgen, Thousand Oaks, CA) to a statin, compared with a statin alone, significantly lowered LDL–cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia, according to the top-line results of the LAPLACE-2 study announced this week. The full results of LAPLACE–2 will be presented by Dr Jennifer Robinson (University of Iowa, …

Continue reading »

Jan 28

Treating statin–intolerant patients with evolocumab (Amgen, Thousand Oaks, CA)

Treating statin–intolerant patients with evolocumab (Amgen, Thousand Oaks, CA) significantly lowers LDL–cholesterol levels, according to the top–line results of the GAUSS–2 study. Evolocumab is an investigational human monoclonal antibody for proprotein convertase subtilisin–kexin type 9 (PCSK9). The study included 307 patients who were unable to tolerate at least two different statins because of muscle–related side …

Continue reading »